DK1626728T3 - Oxiderede lipider og anvendelse heraf ved behandling af inflammatoriske sygdomme og forstyrrelser - Google Patents

Oxiderede lipider og anvendelse heraf ved behandling af inflammatoriske sygdomme og forstyrrelser

Info

Publication number
DK1626728T3
DK1626728T3 DK04735088.9T DK04735088T DK1626728T3 DK 1626728 T3 DK1626728 T3 DK 1626728T3 DK 04735088 T DK04735088 T DK 04735088T DK 1626728 T3 DK1626728 T3 DK 1626728T3
Authority
DK
Denmark
Prior art keywords
disorders
treatment
inflammatory diseases
oxidized lipids
lipids
Prior art date
Application number
DK04735088.9T
Other languages
English (en)
Inventor
Gideon Halperin
Jacob George
Niva Yacov
Eti Kovalevski-Ishai
D Harats
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Application granted granted Critical
Publication of DK1626728T3 publication Critical patent/DK1626728T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/13—Saturated ethers containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1787—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings and having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
DK04735088.9T 2003-05-27 2004-05-27 Oxiderede lipider og anvendelse heraf ved behandling af inflammatoriske sygdomme og forstyrrelser DK1626728T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/445,347 US6838452B2 (en) 2000-11-24 2003-05-27 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
PCT/IL2004/000453 WO2004106486A2 (en) 2003-05-27 2004-05-27 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

Publications (1)

Publication Number Publication Date
DK1626728T3 true DK1626728T3 (da) 2013-09-30

Family

ID=33489370

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04735088.9T DK1626728T3 (da) 2003-05-27 2004-05-27 Oxiderede lipider og anvendelse heraf ved behandling af inflammatoriske sygdomme og forstyrrelser

Country Status (17)

Country Link
US (10) US6838452B2 (da)
EP (1) EP1626728B1 (da)
JP (2) JP5255209B2 (da)
KR (2) KR101122160B1 (da)
CN (2) CN1826122B (da)
AU (1) AU2004243695B2 (da)
CA (1) CA2527483A1 (da)
DK (1) DK1626728T3 (da)
ES (1) ES2429134T3 (da)
HK (1) HK1088234A1 (da)
IL (1) IL172165A (da)
MX (1) MXPA05012784A (da)
NZ (1) NZ544285A (da)
PT (1) PT1626728E (da)
RU (3) RU2362567C2 (da)
WO (1) WO2004106486A2 (da)
ZA (1) ZA200509929B (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20050119301A1 (en) * 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
EP1436313B1 (en) 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US8012483B2 (en) 2004-04-15 2011-09-06 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
RU2399626C2 (ru) * 2004-07-09 2010-09-20 Васкьюлар Байодженикс Лтд. Усовершенствованный способ получения окисленных фосфолипидов
AU2007200090B2 (en) * 2004-07-09 2011-09-22 Vascular Biogenics Ltd. Improved Process for the Preparation of Oxidized Phospholipids
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US7183215B2 (en) * 2004-07-21 2007-02-27 Hewlett-Packard Development Company, L.P. Etching with electrostatically attracted ions
WO2006109170A2 (en) * 2005-04-14 2006-10-19 Esperion Therapeutics Inc. Combination therapy for treatment of cardiovascular diseases and related conditions
EP1957039A2 (en) * 2005-12-09 2008-08-20 Drugtech Corporation Intravenous essential fatty acid emulsion
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
WO2007137864A1 (en) * 2006-06-01 2007-12-06 Eucro European Contract Research Gmbh & Co. Kg Use of inhibitors of pp2c for treating or preventing arteriosclerosis
JP2010502719A (ja) 2006-09-08 2010-01-28 ロード アイランド ホスピタル アルコール誘発性脳疾患の治療、予防および回復
BRPI0719446A2 (pt) 2006-09-28 2013-12-10 Schering Corp Uso de il-10 peguilada para tratar câncer
US8569529B2 (en) * 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) * 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US9034923B2 (en) * 2007-02-08 2015-05-19 Phenomenome Discoveries Inc. Methods for the treatment of senile dementia of the alzheimer's type
WO2009038533A1 (en) * 2007-09-17 2009-03-26 Bioneris Ab Method and means for the treatment of cachexia
US20110230450A1 (en) * 2007-10-16 2011-09-22 Vascular Biogenics Lts Platelet-activating factor (paf) analogs and uses thereof
CA2703838A1 (en) * 2007-10-30 2009-05-07 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for cardiovascular disease
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
EP2127639A1 (en) * 2008-05-26 2009-12-02 Universiteit Utrecht Holding B.V. Corticosteroid containing liposomes for treatment of cardiovascular diseases
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US8815508B2 (en) * 2008-08-12 2014-08-26 Zinfandel Pharmaceuticals, Inc. Method of identifying disease risk factors
WO2010041242A2 (en) * 2008-10-08 2010-04-15 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
JP5752599B2 (ja) 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド 酸化脂質化合物およびその使用
TWI475989B (zh) 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法
DE102009007853A1 (de) * 2009-02-06 2010-08-12 LMU Ludwig-Maximilians-Universität München Mit Alkylphosphocholinen behandelte Intraokularlinsen zur pharmakologischen Nachstarprophylaxe
MX2011012043A (es) * 2009-05-13 2012-03-29 Protein Delivery Solutions Llc Sistema farmaceutico para suministro transmembrana.
CN102834011B (zh) * 2010-01-05 2016-01-13 脉管生物生长有限公司 使用1-十六烷基-2-(4’-羧基丁基)-甘油-3-磷酸胆碱的治疗
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
EA201691399A1 (ru) 2011-01-10 2016-10-31 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
WO2012166798A2 (en) * 2011-06-01 2012-12-06 Wake Forest University Health Sciences Systems and apparatus for indicating risk of coronary stenosis
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
DE102011103948A1 (de) * 2011-06-06 2012-12-06 B. Braun Melsungen Ag Biopassivierende Beschichtung von Gefäßprothesen mit Nitrocarbonsäuren enthaltenden Phospholipiden
US9796786B2 (en) 2011-08-09 2017-10-24 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
AU2012293646B2 (en) 2011-08-09 2017-08-31 Athera Biotechnologies Ab New antibodies against phosphorylcholine
ES2644132T3 (es) 2011-09-01 2017-11-27 Vertellus Holdings Llc Material biocompatible
CN104066756A (zh) 2011-09-01 2014-09-24 弗特鲁斯专业公司 生产生物相容材料的方法
WO2013033642A1 (en) * 2011-09-01 2013-03-07 Vascular Biogenics Ltd. Formulations and dosage forms of oxidized phospholipids
GB201119363D0 (en) 2011-11-10 2011-12-21 Vertellus Specialities Inc Polymerisable material
US20150320773A1 (en) * 2011-12-12 2015-11-12 Vascular Biogenics Ltd. Treatment of inflammation
JP2015510514A (ja) * 2012-02-16 2015-04-09 バスキュラー バイオジェニックス リミテッド 乾癬および血管炎症を処置するための方法
WO2014160305A1 (en) * 2013-03-14 2014-10-02 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates and silicon-based linkers
JP2016519108A (ja) * 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
WO2015064960A1 (ko) * 2013-10-29 2015-05-07 울산대학교 산학협력단 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물
KR101639128B1 (ko) * 2013-10-29 2016-07-13 울산대학교 산학협력단 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016041013A1 (en) * 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016084023A1 (en) 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
RU2635665C1 (ru) * 2017-02-16 2017-11-15 Общество с ограниченной ответственностью "БИОН" Способ получения l-a-глицерофосфорилхолина фармакопейного качества
KR101983298B1 (ko) * 2018-06-11 2019-05-29 연세대학교 산학협력단 인플라마좀 매개 염증성 질환의 예방 또는 치료용 약학 조성물
CN108864187B (zh) * 2018-08-06 2020-12-25 兰博尔开封科技有限公司 一种合成氧乐果重要中间体氧硫磷酯的工艺
KR20220082117A (ko) * 2019-02-21 2022-06-16 위니베르시테 끌로드 베르나르 리옹 Ⅰ 항-염증 화합물에 대한 구조화된 분자 벡터 및 이의 용도
NL2025022B1 (en) * 2020-02-28 2021-10-14 Acad Medisch Ct Intervention strategy for prevention or treatment of autoimmune diseases
JP6859562B1 (ja) * 2020-03-31 2021-04-14 株式会社 レオロジー機能食品研究所 脂肪肝改善用組成物
EP4288044A1 (en) * 2021-02-05 2023-12-13 Retrotope, Inc. Methods for assessing a patient's response to treatment of a neurodegenerative disease with deuterated arachidonic acid
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
AU2022394836A1 (en) * 2021-11-22 2024-05-30 Institute Of Rheological Function Of Food Co., Ltd. Compound, racemate of said compound, salt of said compound or said racemate, composition, anti-inflammatory agent, therapeutic agent for dementia, and therapeutic agent for rett syndrome
WO2024086663A1 (en) * 2022-10-19 2024-04-25 Corner Therapeutics, Inc. Ether lipids for hyperactivation of mammalian dendritic cells

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572226A (en) 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CH642665A5 (en) * 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4410237A (en) 1980-09-26 1983-10-18 Massachusetts Institute Of Technology Method and apparatus for shaping electromagnetic beams
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
AT383130B (de) 1984-05-15 1987-05-25 Chemie Linz Ag Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin
JPS6168494A (ja) * 1984-09-11 1986-04-08 Kao Corp 燐脂質誘導体およびそれを含有する消炎鎮痛剤
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
JPH0617307B2 (ja) * 1984-11-09 1994-03-09 武田薬品工業株式会社 抗腫瘍剤
US4827011A (en) 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
EP0215942B1 (en) 1985-03-15 1995-07-12 Antivirals Inc. Polynucleotide assay reagent and method
US4711512A (en) 1985-07-12 1987-12-08 Environmental Research Institute Of Michigan Compact head-up display
DE3663522D1 (en) 1985-11-29 1989-06-29 Takeda Chemical Industries Ltd Phospholipid derivatives, their production and use
WO1987005904A1 (en) * 1986-03-24 1987-10-08 The University Of Sydney Antigenic analogues of platelet activating factor (paf)
AU7285487A (en) * 1986-04-07 1987-11-09 Upjohn Company, The Anthelmintic quaternaryalkyl acylhydrazones, method of use and compositions
JPS6294A (ja) * 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JPS6354386A (ja) 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPS63135395A (ja) 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
JPH01258691A (ja) * 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JP2534894B2 (ja) 1988-06-24 1996-09-18 日本ケミファ株式会社 新規なグリセリン誘導体およびその誘導体を含有する血圧降下剤
JPH0248585A (ja) * 1988-08-10 1990-02-19 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
US5237451A (en) 1989-11-17 1993-08-17 Minnesota Mining And Manufacturing Company Beam shaping system using diffraction
US5082629A (en) 1989-12-29 1992-01-21 The Board Of The University Of Washington Thin-film spectroscopic sensor
JPH03258740A (ja) 1990-03-06 1991-11-19 Kao Corp 液体油、その製造法及びこれを含有する化粧料
ES2019552A6 (es) 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
JP2869572B2 (ja) 1990-05-14 1999-03-10 和光純薬工業株式会社 ホスファチジルコリン誘導体の製造方法
JPH0497201A (ja) 1990-08-10 1992-03-30 Matsushita Electric Ind Co Ltd ビームエキスパンド装置および回折格子の製造方法
EP0575518A1 (en) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5224198A (en) 1991-09-30 1993-06-29 Motorola, Inc. Waveguide virtual image display
US5561052A (en) * 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
JPH06230225A (ja) 1993-02-03 1994-08-19 Nissan Motor Co Ltd 表示装置
JPH06250022A (ja) 1993-02-26 1994-09-09 Nissan Motor Co Ltd 表示装置
JP3623250B2 (ja) 1993-06-23 2005-02-23 オリンパス株式会社 映像表示装置
US5635385A (en) 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
CA2174510A1 (en) 1993-10-22 1995-04-27 John C. C. Fan Head-mounted display system
DE4440819A1 (de) * 1993-11-19 1995-05-24 Ciba Geigy Ag Photoempfindliche Zusammensetzungen
FR2714382B1 (fr) * 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
JPH07224076A (ja) * 1994-02-10 1995-08-22 Sagami Chem Res Center ホスホリパーゼａ２の阻害剤
AU1751795A (en) 1994-03-04 1995-09-18 University Of British Columbia, The Liposome compositions and methods for the treatment of atherosclerosis
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JP3364313B2 (ja) 1994-03-22 2003-01-08 株式会社トクヤマ ポルフィリン／インジウム錯体及び陰イオン感応膜
US6579697B1 (en) 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
JPH07326065A (ja) 1994-05-27 1995-12-12 Hitachi Ltd 光情報処理装置
US5747340A (en) 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
US5906827A (en) 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
AU3216695A (en) 1994-08-29 1996-03-22 University Of North Carolina At Chapel Hill, The Lipid analogs for treating viral infections
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5506929A (en) 1994-10-19 1996-04-09 Clio Technologies, Inc. Light expanding system for producing a linear or planar light beam from a point-like light source
JPH08208548A (ja) 1995-02-01 1996-08-13 Kao Corp グリセリン誘導体の製造法
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5660855A (en) 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6261597B1 (en) * 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US5916763A (en) 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
US6825980B2 (en) 1995-12-18 2004-11-30 Metrologic Instruments, Inc. DOE-based systems and devices for producing laser beams having modified beam characteristics
JP2001503273A (ja) 1996-11-08 2001-03-13 オクラホマ メディカル リサーチ ファウンデーション Ｅｐｃｒ制御エレメントにより調節される内皮特異的発現
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
EP0954283B1 (en) 1996-12-30 2007-03-21 Battelle Memorial Institute Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation
US6206917B1 (en) 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
EP1007673B1 (en) 1997-07-30 2008-12-17 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6204055B1 (en) 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
JP3781877B2 (ja) * 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
EP0909532A1 (en) 1997-10-16 1999-04-21 Development Center For Biotechnology Environmentally compatible porous material comprising beneficial nematodes and its preparation
CA2307743A1 (en) 1997-10-30 1999-05-14 The General Hospital Corporation Bonding of cartilaginous matrices using isolated chondrocytes
ATE254291T1 (de) 1998-04-02 2003-11-15 Elop Electrooptics Ind Ltd Optische holographische vorrichtungen
AU752285B2 (en) 1998-05-07 2002-09-12 University Of Maryland At Baltimore A method for diagnosing and treating chronic pelvic pain syndrome
US6239151B1 (en) 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
DE19838837A1 (de) 1998-08-27 2000-03-02 Boehringer Ingelheim Int Zellspezifische Promoter des Entkopplungsproteins 3
US20020164434A1 (en) 1998-09-29 2002-11-07 Michael Tarvin Ultra violet light curable floor coating with coloring agent
US6583127B1 (en) * 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents
US6414168B1 (en) * 1998-12-28 2002-07-02 Caschem, Inc. Epoxidation of ricinic compounds using a phase-transfer catalyst
JP3622556B2 (ja) 1999-02-23 2005-02-23 セイコーエプソン株式会社 照明光学系および投写型表示装置
IL130608A0 (en) 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6348583B1 (en) 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US6353032B1 (en) * 1999-11-09 2002-03-05 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
US6989153B2 (en) 1999-11-30 2006-01-24 Varian Medical Systems Technologies, Inc. Radiation sensitive liposomes
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6687360B2 (en) * 1999-12-30 2004-02-03 At&T Corp. Personal IP follow-me service
TWI238183B (en) * 2000-01-12 2005-08-21 Sumitomo Chemical Co Polymeric fluorescent substance and polymer light-emitting device
US6265216B1 (en) 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6866864B2 (en) 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
DE60113976T2 (de) * 2000-03-31 2006-07-27 The Regents Of The University Of California, Oakland Funktionaler nachweis von lipoprotein mit hoher dichte
US6652583B2 (en) 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
JP2002122783A (ja) 2000-10-13 2002-04-26 Olympus Optical Co Ltd 観察光学系及び撮像光学系及びそれを用いた装置
JP2004512402A (ja) 2000-10-25 2004-04-22 アクゾ　ノーベル　ナムローゼ　フェンノートシャップ 光活性型水性コーティング組成物
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
MXPA03004325A (es) 2000-11-17 2004-01-26 Vascular Biogenics Ltd Promotores que muestran especificidad celular endotelial y metodos para su uso.
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CA2429817C (en) * 2000-11-24 2013-02-12 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1363640B1 (en) 2001-01-29 2010-04-28 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
US6458588B1 (en) 2001-01-31 2002-10-01 The General Hospital Corporation Renal stem cells and uses thereof
KR20020083737A (ko) 2001-04-30 2002-11-04 삼성전자 주식회사 착용형 디스플레이 시스템
US6438802B1 (en) 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2003013434A2 (en) 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
US6833955B2 (en) 2001-10-09 2004-12-21 Planop Planar Optics Ltd. Compact two-plane optical device
EP1436313B1 (en) 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
DE10155095A1 (de) 2001-11-09 2003-05-22 Cognis Deutschland Gmbh Alkyl(en)ylglycerinethercarbonsäuren
KR100450815B1 (ko) 2002-02-01 2004-10-01 삼성전자주식회사 조명계 및 이를 채용한 프로젝션 디스플레이 장치
US6757105B2 (en) 2002-04-25 2004-06-29 Planop Planar Optics Ltd. Optical device having a wide field-of-view for multicolor images
US7023622B2 (en) 2002-08-06 2006-04-04 Dmetrix, Inc. Miniature microscope objective lens
US6805490B2 (en) 2002-09-30 2004-10-19 Nokia Corporation Method and system for beam expansion in a display device
US7270425B2 (en) 2002-12-26 2007-09-18 Sanyo Electric Co., Ltd. Projection type video display
JP2005050666A (ja) 2003-07-28 2005-02-24 Tokai Rubber Ind Ltd 燃料電池用ホース材料およびそれを用いてなる燃料電池用ホース
AU2004269409A1 (en) 2003-08-29 2005-03-10 Regents Of The University Of Minnesota Kidney derived stem cells and methods for their isolation, differentiation and use
US7184617B2 (en) 2004-03-12 2007-02-27 Matsushita Electric Industrial Co., Ltd. Portable device
US7123693B2 (en) * 2004-03-13 2006-10-17 Intrado Inc. Method and apparatus for increasing the reliability of an emergency call communication network
US7177398B2 (en) * 2004-03-13 2007-02-13 Intrado Inc. Bi-directional messaging for an emergency services network
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
RU2399626C2 (ru) 2004-07-09 2010-09-20 Васкьюлар Байодженикс Лтд. Усовершенствованный способ получения окисленных фосфолипидов
US20080063656A1 (en) 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
KR101157230B1 (ko) * 2004-08-17 2012-06-15 삼성코닝정밀소재 주식회사 나노 기공을 포함하는 물질을 형성하기 위한 조성물
US20060056028A1 (en) 2004-09-13 2006-03-16 Wildnauer Kenneth R Apodized diffraction grating with improved dynamic range
US20060194765A1 (en) 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
US7206107B2 (en) 2004-12-13 2007-04-17 Nokia Corporation Method and system for beam expansion in a display device
US20090232808A1 (en) 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
WO2007014001A2 (en) * 2005-07-21 2007-02-01 The Board Of Trustees Of The Leland Stanford Junior University Multiplex determination of lipid specific binding moieties
WO2007027905A2 (en) 2005-08-31 2007-03-08 Science And Technology Corporation @ Unm Human renal stem cells
US20080043334A1 (en) 2006-08-18 2008-02-21 Mirage Innovations Ltd. Diffractive optical relay and method for manufacturing the same
EP1932051A1 (en) 2005-09-14 2008-06-18 Mirage Innovations Ltd. Diffraction grating with a spatially varying duty-cycle
EP1764095A1 (en) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
WO2007052265A2 (en) 2005-11-03 2007-05-10 Mirage Innovations Ltd. Binocular optical relay device
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2007138576A1 (en) 2006-05-25 2007-12-06 Mirage Innovations Ltd. Illumination system with optical integrator for an image projector
JP2008037763A (ja) 2006-08-01 2008-02-21 Adeka Corp 抗菌剤及び抗菌剤組成物
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
KR20090011223A (ko) 2007-07-25 2009-02-02 삼성전자주식회사 방송처리장치 및 그 제어방법
AU2008330093A1 (en) 2007-11-28 2009-06-04 Yeda Research And Development Co., Ltd. Method of delaying the onset of clinically definite multiple sclerosis
WO2010041242A2 (en) 2008-10-08 2010-04-15 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
JP5752599B2 (ja) 2008-11-06 2015-07-22 ヴァスキュラー バイオジェニックス リミテッド 酸化脂質化合物およびその使用
US20110083464A1 (en) 2009-10-12 2011-04-14 Craig Kettles Refrigerator with a Pullout Refrigerator Compartment
EP3159405B8 (en) 2010-01-05 2018-11-07 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
EP2521777B1 (en) 2010-01-05 2016-12-28 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma gbm
CN102834011B (zh) 2010-01-05 2016-01-13 脉管生物生长有限公司 使用1-十六烷基-2-(4’-羧基丁基)-甘油-3-磷酸胆碱的治疗
WO2013033642A1 (en) 2011-09-01 2013-03-07 Vascular Biogenics Ltd. Formulations and dosage forms of oxidized phospholipids

Also Published As

Publication number Publication date
JP2013079247A (ja) 2013-05-02
KR101122160B1 (ko) 2012-04-12
US20070099868A1 (en) 2007-05-03
RU2482854C2 (ru) 2013-05-27
CN1826122B (zh) 2010-12-22
US20030225035A1 (en) 2003-12-04
ES2429134T3 (es) 2013-11-13
WO2004106486A3 (en) 2005-01-06
US6838452B2 (en) 2005-01-04
KR101081977B1 (ko) 2011-11-09
US7893291B2 (en) 2011-02-22
WO2004106486A2 (en) 2004-12-09
EP1626728A4 (en) 2009-09-02
IL172165A (en) 2015-10-29
CN102040621A (zh) 2011-05-04
ZA200509929B (en) 2006-12-27
RU2009112686A (ru) 2010-10-20
CN102040621B (zh) 2016-01-20
US20120329757A1 (en) 2012-12-27
MXPA05012784A (es) 2006-02-28
PT1626728E (pt) 2013-10-08
RU2362567C2 (ru) 2009-07-27
NZ544285A (en) 2008-11-28
JP2007531706A (ja) 2007-11-08
US7625882B2 (en) 2009-12-01
CA2527483A1 (en) 2004-12-09
HK1088234A1 (en) 2006-11-03
US8563534B2 (en) 2013-10-22
CN1826122A (zh) 2006-08-30
KR20110036125A (ko) 2011-04-06
US20090209775A1 (en) 2009-08-20
US7186704B2 (en) 2007-03-06
US20050272813A1 (en) 2005-12-08
US20100048515A1 (en) 2010-02-25
RU2013107800A (ru) 2014-08-27
US7902176B2 (en) 2011-03-08
JP5255209B2 (ja) 2013-08-07
RU2005140666A (ru) 2006-06-27
AU2004243695A1 (en) 2004-12-09
US7973023B2 (en) 2011-07-05
US8158611B2 (en) 2012-04-17
EP1626728A2 (en) 2006-02-22
US7504388B2 (en) 2009-03-17
US8501715B2 (en) 2013-08-06
KR20060006973A (ko) 2006-01-20
US20110189212A1 (en) 2011-08-04
US20040106677A1 (en) 2004-06-03
US20110097350A1 (en) 2011-04-28
EP1626728B1 (en) 2013-07-10
AU2004243695B2 (en) 2010-12-02
US20080261865A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
DK1626728T3 (da) Oxiderede lipider og anvendelse heraf ved behandling af inflammatoriske sygdomme og forstyrrelser
IS2873B (is) 2,4-pýrímídíndíamín gagnleg við meðhöndlun á æxlissjúkdómum, bólgu- og ónæmiskerfiskvillum
NO20041588L (no) Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser
IL181706A0 (en) The treatment of inflammatory disorders and pain
IS8451A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
IS8305A (is) Bindandi smíðar og aðferðir við notkun þeirra
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
DK1793855T4 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
DK1765322T3 (da) Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
EP1804813A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
IS8134A (is) Píperasínafleiður og notkun þeirra til að meðhöndla tauga- og geðsjúkdóma
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
IS8083A (is) Notkun á olíu sem inniheldur þríglýseríða með gamma-línólínsýruleifum og línólsýruleifum við meðhöndlun á taugahrörnunarsjúkdómum
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
EP1744740A4 (en) PHENOXYALKYCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
IS7811A (is) Aðferðir og prófefni til að meðhöndla sjúkdóma ogkvilla sem tengjast auknu magni af bólguvaldandi frumuboðum
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme